Release Date: 06/12/18 09:22 Summary: Completion of strategic review and business update Price Sensitive: Yes Download Document 141.61KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%